share_log

T2 Biosystems | 8-K: T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

T2 Biosystems | 8-K: T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

T2 Biosystems | 8-K：T2 Biosystems成功申请欧盟全血病原体直接检测方法专利
美股SEC公告 ·  09/20 09:02

Moomoo AI 已提取核心信息

On September 20, 2024, T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced the successful defense of a key patent for its direct-from-whole blood detection method in the European Union. The patent, which is central to T2 Biosystems' intellectual property portfolio, faced opposition from bioMerieux and other undisclosed firms, filed with the European Patent Office (EPO) in May 2023. The EPO's Opposition Division held a public hearing on September 19, 2024, and ruled in favor of maintaining T2 Biosystems' patent, reinforcing the company's strong intellectual property position. The patent in question, European Patent No. 3 443 124, pertains to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This victory is significant for T2 Biosystems as it continues to advance its technology, commercial platform, and product pipeline.
On September 20, 2024, T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced the successful defense of a key patent for its direct-from-whole blood detection method in the European Union. The patent, which is central to T2 Biosystems' intellectual property portfolio, faced opposition from bioMerieux and other undisclosed firms, filed with the European Patent Office (EPO) in May 2023. The EPO's Opposition Division held a public hearing on September 19, 2024, and ruled in favor of maintaining T2 Biosystems' patent, reinforcing the company's strong intellectual property position. The patent in question, European Patent No. 3 443 124, pertains to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This victory is significant for T2 Biosystems as it continues to advance its technology, commercial platform, and product pipeline.
2024年9月20日，t2 biosystems公司，速测败血症病原体的领导者，宣布在欧盟成功捍卫了其直接从全血检测方法的关键专利。该专利是 t2 biosystems 知识产权组合的核心部分，面临来自bioMerieux和其他未透露的公司的反对，这些公司于2023年5月向欧洲专利局（EPO）提出。欧洲专利局的反对司法部于2024年9月19日举行了公开听证会，并裁定支持维护 t2 biosystems 公司的专利，强化了公司强大的知识产权地位。受争议的专利为欧洲专利号3 443 124，涉及在全血样本中扩增病原体的靶核酸的方法。这一胜利对 t2 biosystems 公司来说意义重大，因为该公司不断推进其科技、商业平台和产品管道。
2024年9月20日，t2 biosystems公司，速测败血症病原体的领导者，宣布在欧盟成功捍卫了其直接从全血检测方法的关键专利。该专利是 t2 biosystems 知识产权组合的核心部分，面临来自bioMerieux和其他未透露的公司的反对，这些公司于2023年5月向欧洲专利局（EPO）提出。欧洲专利局的反对司法部于2024年9月19日举行了公开听证会，并裁定支持维护 t2 biosystems 公司的专利，强化了公司强大的知识产权地位。受争议的专利为欧洲专利号3 443 124，涉及在全血样本中扩增病原体的靶核酸的方法。这一胜利对 t2 biosystems 公司来说意义重大，因为该公司不断推进其科技、商业平台和产品管道。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间